Article

Inhibition of Parkinson’s Disease-related LRRK2 by type-I and type-II kinase inhibitors: activity and structures

2023-09-09

Abstract excerpt

Mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are a common cause of familial Parkinson’s Disease (PD), and a risk factor for the sporadic form. Increased kinase activity has been shown in both familial and sporadic PD patients, making LRRK2 kinase inhibitors a major focus of drug development efforts in PD. Although significant progress has been made in understanding the structural biology of LRRK2, there are n...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0c6f18af-584a-5b2c-8291-bf70cd4a0f48
DOI: 10.1101/2023.09.07.556689

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Inhibition of Parkinson’s Disease-related LRRK2 by type-I and type-II kinase inhibitors: activity and structuresDOI 10.1101/2023.09.07.556689Read

Inhibition of Parkinson's disease-related LRRK2 by type I and type II kinase inhibitors: Activity and structures.Semantic proximity Read

Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.Semantic proximity Read

The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease.Semantic proximity Read

Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to dateSemantic proximity Read

Structural biology of Parkinson’s disease-associated leucine-rich repeat kinase 2 (LRRK2)Semantic proximity Read

Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease ModelsSemantic proximity Read

Roc, the G-domain of the Parkinson's disease-associated protein LRRK2.Semantic proximity Read

Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.Semantic proximity Read

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.Semantic proximity Read

LRRK2 in Parkinson's disease: protein domains and functional insights.Semantic proximity Read

Capturing differences in the regulation of LRRK2 dynamics and conformational states by small molecule kinase inhibitorsSemantic proximity Read

Structure of LRRK1 and mechanisms of autoinhibition and activationSemantic proximity Read